OcuSci Inc.

OcuSci Inc. is a manufacturer of clinically proven medical devices and therapeutic products for the treatment of dry eye disease and meibomian gland dysfunction. The company's flagship offering is the MGrx Dry Eye Treatment System, an in-clinic therapeutic device designed to deliver rapid symptom relief—demonstrated within 24 hours of treatment. The MGrx is a non-invasive system that can be administered by clinical staff and generates $300–$400 profit per treatment with ROI achieved within 40 patient cases. Clinical data supports a 51% improvement in OSDI (Ocular Surface Disease Index) scores following treatment. OcuSci also manufactures complementary home-care products including a therapeutic moist-heat Dry Eye Compress and proprietary dry eye supplements (Ultra Dry Eye TG), which together have demonstrated a 42% reduction in dry eye symptoms within 30 days of combined use. The company targets eye care practices, vision clinics, and ophthalmology practices seeking effective, revenue-generating dry eye treatment solutions without disposable product dependencies.